Nathan D. Trinklein
Gründer bei SwitchGear Genomics, Inc.
Aktive Positionen von Nathan D. Trinklein
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
SwitchGear Genomics, Inc.
 SwitchGear Genomics, Inc. BiotechnologyHealth Technology SwitchGear Genomics, Inc. provides products for studying regulatory elements in the human genome. It launches LightSwitch Synthetic Response Element which is used for understanding transcription factor activity in living cells. The firms endogenous human promoter vectors are used in primary screening assays to understand how drug candidates may affect biological pathways. The company was founded by Richard M. Myers, Nathan D. Trinklein and Shelley Force Aldred in 2006 and is headquartered in Menlo Park, CA. | Direktor/Vorstandsmitglied | 01.01.2006 | - |
| Vorstandsvorsitzender | 01.01.2006 | - | |
| Gründer | 01.01.2006 | - | |
Rondo Therapeutics, Inc.
 Rondo Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Rondo Therapeutics, Inc. develops bispecific therapeutic antibodies to fight cancer. The American company was founded by Nathan D. Trinklein, Shelley Force Aldred. Shelley Force Aldred has been the CEO since incorporation. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
| Gründer | 01.08.2021 | - | |
| Präsident | 01.08.2021 | - |
Karriereverlauf von Nathan D. Trinklein
Ausbildung von Nathan D. Trinklein
| Stanford University | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 4 |
Operativ
| Founder | 2 |
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
Sektoral
| Health Technology | 2 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
SwitchGear Genomics, Inc.
SwitchGear Genomics, Inc. BiotechnologyHealth Technology SwitchGear Genomics, Inc. provides products for studying regulatory elements in the human genome. It launches LightSwitch Synthetic Response Element which is used for understanding transcription factor activity in living cells. The firms endogenous human promoter vectors are used in primary screening assays to understand how drug candidates may affect biological pathways. The company was founded by Richard M. Myers, Nathan D. Trinklein and Shelley Force Aldred in 2006 and is headquartered in Menlo Park, CA. | Health Technology |
Rondo Therapeutics, Inc.
Rondo Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Rondo Therapeutics, Inc. develops bispecific therapeutic antibodies to fight cancer. The American company was founded by Nathan D. Trinklein, Shelley Force Aldred. Shelley Force Aldred has been the CEO since incorporation. | Commercial Services |
- Börse
- Insiders
- Nathan D. Trinklein
- Erfahrung
